IL1-blocking therapy in colchicine-resistant familial Mediterranean fever

OBJECTIVE: Approximately 10%–20% of patients with familial Mediterranean fever (FMF) show an inadequate response to colchicine. In our cohort study, patients with FMF with or without amyloidosis and with an inadequate response to colchicine were treated with anakinra or canakinumab. METHODS: Clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Köhler, Birgit Maria, Lorenz, Hanns-Martin, Blank, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medical Research and Education Association 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267760/
https://www.ncbi.nlm.nih.gov/pubmed/30501849
http://dx.doi.org/10.5152/eurjrheum.2018.18036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267760/
https://www.ncbi.nlm.nih.gov/pubmed/30501849
http://dx.doi.org/10.5152/eurjrheum.2018.18036

Ejemplares similares